NCT05749276View on ClinicalTrials.gov

Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions

Adult Patients With Adverse Risk Acute Myeloblastic Leukemia

Interventions

DRUG

Darzalex

"DARZALEX® = Daratumumab. Solution for injection, 1800 mg/15 mL, single vial. Sub-cutaneous administration.~* Dose level 1 : 1800 mg Day 1~* Dose level 2 : 1800 mg Day 1 and 8 (+/- 2 days)~* Dose level 3 : 1800 mg à Day 1, 8 (+/- 2 days) and D15 (+/- 2 days)"

All Listed Sponsors

lead

Nantes University Hospital

OTHER